Kinnate Biopharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Kinnate Biopharma is gedaald met een gemiddeld jaarlijks tempo van -36.4%, terwijl de winst van de sector Biotechs jaarlijks groeide met 19.3%.

Belangrijke informatie

-36.4%

Groei van de winst

7.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-70.7%
Nettomarge	n/a
Laatste winstupdate	31 Dec 2023

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Aug 11

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

May 15

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Jan 24

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Oct 09

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Jun 22

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Mar 03

Kinnate Biopharma earns bulls as IPO quiet period ends

Dec 28

Opbrengsten en kosten

Hoe Kinnate Biopharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:KNTE Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Dec 23	-113	28	91
30 Sep 23	-127	30	103
30 Jun 23	-127	31	102
31 Mar 23	-122	31	95
31 Dec 22	-116	30	88
30 Sep 22	-111	30	82
30 Jun 22	-105	28	78
31 Mar 22	-99	26	74
31 Dec 21	-90	23	67
30 Sep 21	-77	18	60
30 Jun 21	-63	14	49
31 Mar 21	-49	11	39
31 Dec 20	-36	7	29
30 Sep 20	-26	6	20
31 Dec 19	-10	3	9

Kwaliteitswinsten: KNTE is momenteel verliesgevend.

Groeiende winstmarge: KNTE is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: KNTE is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 36.4% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van KNTE over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: KNTE is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: KNTE heeft een negatief Return on Equity ( -70.7% ), omdat het momenteel verliesgevend is.

Kinnate Biopharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Kinnate Biopharma Files Form 15

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index

Price target increased by 21% to US$4.53

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Price target decreased by 84% to US$3.75

Insufficient new directors

Kinnate Biopharma Inc. Announces Workforce Restructuring

New minor risk - Market cap size

Price target increased by 8.1% to US$25.86

Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

Price target decreased by 16% to US$25.00

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Kinnate Biopharma Inc. Appoints Jill DeSimone as Independent Director, Effective on March 1, 2023

Kinnate Biopharma Inc. to Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Price target decreased to US$31.88

High number of new and inexperienced directors

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Kinnate Biopharma Inc. Announces Pipeline Update

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from Russell 2000 Growth Index

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

Price target decreased to US$40.71

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

High number of new and inexperienced directors

Kinnate Biopharma Inc., Annual General Meeting, Jun 10, 2022

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Its FGFR Inhibitor Product Candidate, KIN-3248

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Price target decreased to US$43.43

Chief Medical Officer recently bought US$339k worth of stock

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation At the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Kinnate Biopharma Inc. Announces U.S Food and Drug Administration Clearance of Investigational Drug Application for KIN-3248

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Kinnate Biopharma Inc. Announces That the First Patient Has Commenced Treatment in its Phase 1 KN-8701 Clinical Trial

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Director Stephen Kaldor has left the company

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

New 90-day low: US$29.70

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Kinnate Biopharma earns bulls as IPO quiet period ends

Kinnate Biopharma Inc. has completed an IPO in the amount of $240 million.

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden